Detalhe da pesquisa
1.
Timing and duration of bevacizumab treatment and survival in patients with recurrent ovarian, fallopian tube, and peritoneal cancer: a multi-institution study.
Eur J Gynaecol Oncol
; 44(1): 17-25, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36874058
2.
Characterizing TP53 mutations in ovarian carcinomas with and without concurrent BRCA1 or BRCA2 mutations.
Gynecol Oncol
; 160(3): 786-792, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33375991
3.
Characterization of TP53 mutations in Pap test DNA of women with and without serous ovarian carcinoma.
Gynecol Oncol
; 156(2): 407-414, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31839337
4.
Antiprogestins reduce epigenetic field cancerization in breast tissue of young healthy women.
Genome Med
; 14(1): 64, 2022 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35701800
5.
Uterine lavage identifies cancer mutations and increased TP53 somatic mutation burden in individuals with ovarian cancer.
Cancer Res Commun
; 2(10): 1282-1292, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36311816
6.
Perceptions of risk and reward in BRCA1 and BRCA2 mutation carriers choosing salpingectomy for ovarian cancer prevention.
Fam Cancer
; 19(2): 143-151, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32096072
7.
Correction: Antiprogestins reduce epigenetic field cancerization in breast tissue of young healthy women.
Genome Med
; 14(1): 76, 2022 Jul 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-35854342